Covid-19 Tedavisinde Favipiravir Kullanımı: Tartışılan Konular…

Year 2021, , 5 - 7, 09.03.2021

İzzet Göker Küçük , Kurtuluş Öngel

https://doi.org/10.21763/tjfmpc.787836

Abstract

Ülkemizde 11 Mart 2020’de ilk vakanın görülmesiyle başlayan Covid-19 pandemisi sürecinde, korunma ve tedavi yöntemleri ile ilgili ciddi tartışmalar yaşanmaktadır. Korunma yöntemleri olarak maske kullanımı, sosyal mesafe ve hijyen tedbirleri herkes tarafından kabul edilmiştir. Ancak tedavi yöntemlerinde en sık kafa karıştıran konulardan birisi, mucize ilaç olarak tanıtılan favipiravirde yaşanmaktadır. Mevcut Türkiye Cumhuriyeti Sağlık Bakanlığı uygulamalarına bakınca, önümüzdeki günlerde aile hekimlerinin Covid-19’lu hastaların tedavilerinde daha aktif rol alacaklarını düşündürmektedir. Bu yazıda, favipiravir hakkındaki tartışmalı durumlar ve doğru uygulamaları paylaşmayı amaçlanmıştır.

Keywords

Covid-19, pandemi, favipiravir

Supporting Institution

Yok

Project Number

Yok

Favipiravir Use in Covid-19 Treatment: Discussed Issues…

Abstract

In our country, there is serious debate about prevention and treatment methods during the Covid-19 pandemic, which began with the first case on March 11, 2020.The use of masks, social distance and hygiene measures as protection methods are accepted by everyone. However, one of the most confusing issues in treatment methods is experienced in favipiravir, which is introduced as a miracle drug. Considering the current practices of the Ministry of health of the Republic of Turkey, it suggests that in the coming days, family doctors will take a more active role in the treatment of patients with Covid-19. In this article, weaimed to share controversial situations and correct practices about favipiravir.

Keywords

Covid-19, pandemic, favipiravir

Project Number

Yok

References

• 1. World Health Organization: Launch of SOLIDARITY trial (pres release). https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020. AccessedMarch 18, 2020.
• 2. Remport A, Gerlei Z, Creprekal O, Wagner L, Foldes K, Marton A, et al. Guidance on thespecialcare of liverorkidneytransplantrecipientsdiagnosedwith Covid-19. OrvHetil 2020;161(32):1310-21.
• 3. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potentialcountermeasureagainstneglectedandemerging RNA viruses. AntiviralResearch2018;153:85–94.
• 4. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A review of SARS-CoV-2 andtheongoingclinicaltrials. Int J MolSci 2020;21(7):2657.
• 5. Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M. A global treatmentsforcoronavirusesincluding COVİD-19. J Cell Physiol 2020 May 11; DOI: 10.1002/jcp.29785.
• 6. Shiraki K, Daikoku T. Favipiravir, an anti-influenzadrugagainst life-threateningRNA virusinfections. Pharmacology&Therapeutics2020;209:107512.
• 7. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potentialcountermeasureagainstneglectedandemerging RNA viruses. AntiviralResearch2018;153:85–94.
• 8. Cai Q, Yang M, Liu D, et al. Experimentaltreatmentwithfavipiravirfor COVID-19: an open-labelcontrolstudy. Engineering (Beijing). Epubahead of print 18 March 2020. DOI: 10.1016/j.eng.2020.03.007.
• 9. Yenerçağ M, Arslan U, Doğduş M, Günal Ö, Öztürk ÇE, Aksan G, et al. Evaluation of electrocardiographicventricularrepolarizationvariables in patientswithnewlydiagnosed COVID-19. J Electrocardiol 2020;62:5–9.